Biosenta Inc.
ZRO
CNSX
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -66.67% | 200.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -66.67% | 200.00% | |||
| Cost of Revenue | -50.00% | -92.31% | |||
| Gross Profit | 0.00% | 104.00% | |||
| SG&A Expenses | -31.60% | -25.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -39.19% | -18.31% | |||
| Operating Income | 39.17% | 18.35% | |||
| Income Before Tax | 91.11% | -958.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 91.11% | -958.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 91.11% | -958.60% | |||
| EBIT | 39.17% | 18.35% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 88.09% | -587.50% | |||
| Normalized Basic EPS | -41.38% | 42.00% | |||
| EPS Diluted | 88.09% | -587.50% | |||
| Normalized Diluted EPS | -41.38% | 42.00% | |||
| Average Basic Shares Outstanding | -25.27% | 53.56% | |||
| Average Diluted Shares Outstanding | -25.27% | 53.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
